期刊文献+

支气管扩张症急性加重期患者的病原菌药敏分析 被引量:1

Analysis of Antibiotic Susceptibility of the Patients with Acute Exacerbating Bronchiectasis
下载PDF
导出
摘要 目的探讨支气管扩张症急性加重期患者的病原菌药敏情况。方法对该院收治的64例支气管扩张症急性加重期患者的的痰细菌药敏结果进行回顾性分析。结果 64例患者中,培养阳性34例,铜绿假单胞菌18株,大肠埃希氏菌4株,肺炎克雷伯杆菌4株;铜绿假单胞菌的药敏结果中,对头孢哌酮/舒巴坦、哌拉西林/他唑巴坦、碳氢霉烯类抗生素等敏感性较高。结论支气管扩张症急性加重期患者针对性选择细菌敏感的抗菌药物,减少耐药菌的产生。 Objective To analyse the bacterial drug resistance of the patients with acute exacerbations of bronchiectasis. Methods We performed a retrospective investigation ,64 patients with acute exacerbations of bronchiectasis ,who were hospitalized in 2009~2012 carried on the analysis of sputum bacterial drug sensitive experiment. Results The sputum bacterial cultivation positive 34 cases among the 64 bronchiectasis patients, Pseudomonas aeruginosa strain 18 , Escherichia coli 4 strains ,Klebsiella pneumonia in 4 strains .In response to Pseudomonas aeruginosa susceptibility results, to Cefoperazone / sulbactam, piperacillin / tazobactam, hydrocarbon of carbapenem antibiotics such as higher sensitivity. Conclusion It should be targeted to choose their sensitive antibiotics for patients with acute exacerbation, reduce the emergence of resistant bacteria.
作者 武文娟
出处 《中外医疗》 2013年第12期90-91,共2页 China & Foreign Medical Treatment
关键词 支气管扩张症 急性加重期 病原菌药敏 Bronchiectasis Acute exacerbations Bacilliculture drug sensitive experiment
  • 相关文献

参考文献4

二级参考文献55

  • 1丁震,孙耕耘,李家斌.合肥市产超广谱β-内酰胺酶菌株中OXA型ESBLs基因分布[J].中华医院感染学杂志,2005,15(2):124-126. 被引量:13
  • 2李涛,熊自忠,沈继录,周强,徐元宏,王中新.大肠埃希菌与克雷伯菌属细菌qnr基因的检测[J].检验医学,2005,20(2):112-114. 被引量:35
  • 3赵宗珉,陈佰义.抗生素轮换和替换(干预)与控制细菌耐药[J].中华内科杂志,2007,46(7):596-598. 被引量:19
  • 4Bantar C, Vesco E, Heft C, et al. Replacement of broad-spectrum cephalosporins by piperacillin-tazobactam: impact on sustained high rates of bacterial resistance. Antimierob Agents Cbemotber, 2004,48: 392-395.
  • 5Gruson D, Hilbert G, Vargas F, et al. Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram negative bacilli responsible for ventilator-associated pneumonia. Crit Care Med,2003.31:1908-1914.
  • 6Bradley SJ, Wilson AL, Allen MC. et al. The control of hyperendemlc glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. Antimicrob Chemother. 1999.43:261-266.
  • 7Li C, Nicolau DP,Lister PD, et al. Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase. J Antimicrob Chemother, 2004, 53: 297-304.
  • 8Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev, 2001, 14 : 933- 951.
  • 9Coulton S, Francois I. Beta-Lactamases: targets of drug design. Prog Med Chem,1994,31:297-349.
  • 10Pallecchi L, Malossi M, Mantella A, et al. Detection of CTX-M- type β-lactamase genes in fecal Escherichia coil isolates from healthy children in Bolivia and Peru. Antimicrob Agents Chemother, 2004.48 :4556-4561.

共引文献170

同被引文献13

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部